138 related articles for article (PubMed ID: 7981447)
21. Serum markers and prognosis in locally advanced breast cancer.
Martínez-Trufero J; de Lobera AR; Lao J; Puértolas T; Artal-Cortés A; Zorrilla M; Alonso V; Pazo R; Valero MI; Ríos-Mitchell MJ; Calderero V; Herrero A; Antón A
Tumori; 2005; 91(6):522-30. PubMed ID: 16457152
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of tumor markers in southern Indian breast cancer patients.
Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
[TBL] [Abstract][Full Text] [Related]
23. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
24. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
Barrenetxea G; Schneider J; Llorente MF
Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
[No Abstract] [Full Text] [Related]
25. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
Sütterlin M; Bussen S; Trott S; Caffier H
Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
[TBL] [Abstract][Full Text] [Related]
26. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
Sölétormos G; Petersen PH; Dombernowsky P
Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
[TBL] [Abstract][Full Text] [Related]
27. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
28. Cancer associated serum antigen (CASA) levels in patients with breast carcinoma and in 3 control groups without breast cancer.
Meisel M; Weise J; Schwesinger G; Straube W
Arch Gynecol Obstet; 1998; 261(3):159-62. PubMed ID: 9651660
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
31. Circulating epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) in patients with epithelial ovarian carcinoma.
Shah NG; Bhatavdekar JM; Doctor SS; Suthar TP; Balar DB; Dave RS
Neoplasma; 1994; 41(5):241-3. PubMed ID: 7854492
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
[TBL] [Abstract][Full Text] [Related]
33. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
[TBL] [Abstract][Full Text] [Related]
34. Serum CA 15.3, CEA and ESR patterns in breast cancer.
Rubach M; Szymendera JJ; Kamińska J; Kowalska M
Int J Biol Markers; 1997; 12(4):168-73. PubMed ID: 9582607
[TBL] [Abstract][Full Text] [Related]
35. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer.
Sonoo H; Kurebayashi J
Surg Today; 1996; 26(4):250-7. PubMed ID: 8727945
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients.
Hodorowicz-Zaniewska D; Kibil W; Małek A; Szpor J; Kulig J; Sztefko K
Pol J Pathol; 2012 Dec; 63(4):255-60. PubMed ID: 23359195
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.
Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Altorjai G; Locker GJ; Mader R; Zielinski CC; Steger GG
BMC Cancer; 2006 Mar; 6():81. PubMed ID: 16563172
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
40. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.
Fu Y; Li H
Med Sci Monit; 2016 Sep; 22():3154-62. PubMed ID: 27596019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
